Over 10,000 Hepatitis C Patients Recover in Sofosbuvir | Daily Express Online

Over 10,000 hepatitis C patients recover with sofosbuvir

Release date: Tuesday, June 15, 2021

Posted by: Bernama

font size:

Kuala Lumpur: In Malaysia, more than 10,000 patients in Malaysia have hepatitis C after combining the new drug Ravidasvir with the existing affordable direct-acting antiviral (DAA) drug sofosbuvir within 3-6 months of treatment. Healed the virus (HCV). Datuk Dr Muhammad Radzi Abu Hassan, Head of Gastroenterology and Hepatology at the Ministry of Health (MOH), said the treatment could reduce the risk of death from chronic liver disease and set Malaysia’s goal of eradicating HCV by 2030. He said it would be in line. Therefore, the disease has changed the situation of hepatitis C, including people infected with genotype 3 of the virus, which is treatable and especially difficult to treat.

Advertising

“For me, the number of people who have been cured is a big achievement given the situation of COVID-19 in the country and started in mid-2018,” he said at a virtual press conference on hepatitis C treatment today. It was. Among the panelists are Health Director Dr. Tan Sri, Noor Hisham Abdullah, Falco Corporation (Falco) Chief Executive Officer, Dr. Sherine Helmy, Pharmaniaga Bird (Farmaniaga) Regulatory Director, Sharifah Fauzija. Included Sayed Motorle, Drug Initiative for Neglected Diseases (DNDi) South Asia. Director of Southeast Asia, Jean-Michel Piedagnel and Director of Third World Network, Chiyokelin. Dr. Muhammad Radzi said MOH is aggressively screening by deploying diagnostic tests in all medical facilities and expanding to prisons, rehab centers, general practitioners and private centers to enable more patients to be treated. Said that they are implementing. Ravidasvir is the first drug for HCV developed with funding and clinical support from a non-profit organization through South-South cooperation.

Advertising

On June 4, the Drug Control Authority (DCA) granted conditional enrollment of Ravida Tablets 200 mg (Ravidasvir Hydrochloride 200 mg), a safe and effective hepatitis C treatment developed by a public-private partnership. The partnership brings together MOH, the non-profit R & D organization DNDi, the Egyptian pharmaceutical company Pharmaco, the Malaysian pharmaceutical company Pharmamaniaga, and the non-governmental organization Doctors Without Borders (MSF). Meanwhile, Dr. Noor Hisham said MOH is considering an integrated strategy to make diagnostic tests and treatments for hepatitis C available to the community. “Our current intention is not only to decentralize from tertiary to primary care, but also to make it available in all clinics in both urban and rural areas. In Malaysia, from Perlis to Sabah. There are more than 3,000 clinics up to Tawau, state. “This is an important integration strategy. This is the way we approach using public health measures. Investing in public health is very important to us. This is a place that needs prevention and will be a national cost-cutting measure over the next decade, “he said. Dr. Noor Hisham said it will take several months for MOH to roll out procurement in all clinics by the last quarter of this year or next year as DCA approves Ravidasvir. He also said that MOH is exploring the possibility of treating hepatitis C patients in just eight weeks compared to the current 12-week treatment, thus reducing costs by a third. “… Looking at the cost of US $ 300 at a competitive market price, we expect it to drop to US $ 200. That is our goal. I am achievable and hopefully in the future. In a few years, I think it will be much cheaper. It’s probably 10 years from now to deploy this treatment, and we expect it to be less than US $ 100, “he added.